Plus Therapeutics (FRA:XMP1) Other Financing: €-10.71 Mil (TTM As of Mar. 2026)


FRA:XMP1 Plus Therapeutics Inc FRA:XMP1
22 GF Score
Price €3.38
! 2 Warning Signs
View Full Analysis

What is Plus Therapeutics Other Financing?

Plus Therapeutics FRA:XMP1 -3.01% 22 Other Financing is €-10.71 Mil as of Mar. 2026. GuruFocus rates FRA:XMP1 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Plus Therapeutics's Other Financing for the three months ended in Mar. 2026 was €-5.07 Mil.

Plus Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-10.71 Mil.

Plus Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Plus Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Plus Therapeutics Other Financing Chart

Plus Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.79 -0.73 -0.32 0.00 -4.89

Plus Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 -0.19 -4.63 -0.81 -5.07
FRA:XMP1
22GF Score
Plus Therapeutics Inc FRA:XMP1
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Plus Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-10.71 Mil mean?
Plus Therapeutics (FRA:XMP1) has a Other Financing of €-10.71 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Plus Therapeutics and its competitors.
Is Plus Therapeutics' Other Financing too high?
Plus Therapeutics' current Other Financing is €-10.71 Mil. Overall, Plus Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' Other Financing compare to GRCE and NNVC?
Plus Therapeutics' Other Financing of €-10.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Plus Therapeutics and its competitors. Plus Therapeutics's current Other Financing is €-10.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (FRA:XMP1) has a current Other Financing of €-10.71 Mil. The current Other Financing is €-10.71 Mil. Plus Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Plus Therapeutics (FRA:XMP1), the current Other Financing is €-10.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plus Therapeutics Business Description

Other Exchanges PSTV:USA
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
22GF Score

Get the complete analysis for FRA:XMP1

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.38
Price